A股異動 | 凱美特氣(002549.SZ)漲停 疫苗催生對乾冰需求大增
格隆匯12月10日丨凱美特氣(002549.SZ)漲停,報8.94元創逾三個月新高,最新總市值55.76億,換手率5.3%,現有封單19萬餘手。由於輝瑞等新冠疫苗需要極低温儲存,冷鏈物流成為疫苗存儲、分發和接種的新難題。大劑量的疫苗運輸需要大量乾冰,對乾冰的需求也隨之上升,目前某些地區乾冰運輸的價格已上升至平常價格的20倍。有乾冰生產商表示,自從11月份輝瑞疫苗傳出重大利好時,他們就已經接到生產需求,並開始加購機器趕製。公司主營業務包括以食品添加劑液體二氧化碳的生產及銷售為主,並進行乾冰及其他工業氣體的生產及銷售。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.